, , and Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study

English version České info

Background:
To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%–50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined effect of variants of IL28B with human leukocyte antigen C (HLA-C), and its ligands the killer immunoglobulin-like receptors (KIR), which have previously been implicated in HCV viral control.

Methods and Findings:
We genotyped chronic hepatitis C (CHC) genotype 1 patients with PegIFN/R treatment-induced clearance (n = 417) and treatment failure (n = 493), and 234 individuals with spontaneous clearance, for HLA-C C1 versus C2, presence of inhibitory and activating KIR genes, and two IL28B SNPs, rs8099917 and rs12979860. All individuals were Europeans or of European descent. IL28B SNP rs8099917 “G” was associated with absence of treatment-induced clearance (odds ratio [OR] 2.19, p = 1.27×10⁻⁸, 1.67–2.88) and absence of spontaneous clearance (OR 3.83, p = 1.71×10⁻¹⁴, 2.67–5.48) of HCV, as was rs12979860, with slightly lower ORs. The HLA-C C2C2 genotype was also over-represented in patients who failed treatment (OR 1.52, p = 0.024, 1.05–2.20), but was not associated with spontaneous clearance. Prediction of treatment failure improved from 66% with IL28B to 80% using both genes in this cohort (OR 3.78, p = 8.83×10⁻⁶, 2.03–7.04). There was evidence that KIR2DL3 and KIR2DS2 carriage also altered HCV treatment response in combination with HLA-C and IL28B.

Conclusions:
Genotyping for IL28B, HLA-C, and KIR genes improves prediction of HCV treatment response. These findings support a role for natural killer (NK) cell activation in PegIFN/R treatment-induced clearance, partially mediated by IL28B.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: , , and Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Med 8(9): e32767. doi:10.1371/journal.pmed.1001092
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001092

Souhrn

Zdroje

1. MicallefJMKaldorJMDoreGJ 2006 Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13 34 41

2. HoofnagleJH 2002 Course and outcome of hepatitis C. Hepatology 36 S21 S29

3. FeldJJHoofnagleJH 2005 Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 967 972

4. GeDFellayJThompsonAJSimonJSShiannaKV 2009 Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 399 401

5. SuppiahVMoldovanMAhlenstielGBergTWeltmanM 2009 IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41 1100 1104

6. TanakaYNishidaNSugiyamaMKurosakiMMatsuuraK 2009 Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41 1105 1109

7. ThomasDLThioCLMartinMPQiYGeD 2009 Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461 798 801

8. AfdhalNHMcHutchisonJGZeuzemSMangiaAPawlotskyJM 2011 Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 53 336 345

9. ColonnaMBorsellinoGFalcoMFerraraGBStromingerJL 1993 HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A 90 12000 12004

10. WagtmannNRajagopalanSWinterCCPeruzziMLongEO 1995 Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 3 801 809

11. NumasakiMTagawaMIwataFSuzukiTNakamuraA 2007 IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 178 5086 5098

12. SatoAOhtsukiMHataMKobayashiEMurakamiT 2006 Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176 7686 7694

13. KhakooSIThioCLMartinMPBrooksCRGaoX 2004 HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 872 874

14. KnappSWarshowUHegazyDBrackenburyLGuhaIN 2010 Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51 1168 1175

15. Vidal-CastineiraJRLopez-VazquezADiaz-PenaRAlonso-AriasRMartinez-BorraJ 2009 Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 84 475 481

16. AhlenstielGMartinMPGaoXCarringtonMRehermannB 2008 Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 118 1017 1026

17. DoreGJHellardMMatthewsGVGrebelyJHaberPS 2010 Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 138 123 135 e121–122

18. AitkenCKLewisJTracySLSpelmanTBowdenDS 2008 High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48 1746 1752

19. WittCSPricePKaurGCheongKKangaU 2002 Common HLA-B8-DR3 haplotype in Northern India is different from that found in Europe. Tissue Antigens 60 474 480

20. KulkarniSMartinMPCarringtonM 2010 KIR genotyping by multiplex PCR-SSP. Methods Mol Biol 612 365 375

21. AshouriEGhaderiAReedEFRajalingamR 2009 A novel duplex SSP-PCR typing method for KIR gene profiling. Tissue Antigens 74 62 67

22. DunneCCrowleyJHaganRRooneyGLawlorE 2008 HLA-A, B, Cw, DRB1, DQB1 and DPB1 alleles and haplotypes in the genetically homogenous Irish population. Int J Immunogenet 35 295 302

23. WilliamsFMeenaghAPattersonCMiddletonD 2002 Molecular diversity of the HLA-C gene identified in a caucasian population. Hum Immunol 63 602 613

24. AhlenstielGBoothDRGeorgeJ 2010 IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol 45 903 910

25. DringMMMorrisonMHMcSharryBPGuinanKJHaganR 2011 Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A 108 5736 5741

26. AhlenstielGTiterenceRHKohCEdlichBFeldJJ 2010 Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 138 325 335 e321–322

27. LeeSHMiyagiTBironCA 2007 Keeping NK cells in highly regulated antiviral warfare. Trends Immunol 28 252 259

28. StegmannKABjorkstromNKVeberHCiesekSRieseP 2010 Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138 1885 1897

29. MarcelloTGrakouiABarba-SpaethGMachlinESKotenkoSV 2006 Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131 1887 1898

30. HondaMSakaiAYamashitaTNakamotoYMizukoshiE 2010 Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139 499 509

31. KwoPYLawitzEJMcConeJSchiffERVierlingJM 2010 Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376 705 716

32. McHutchisonJGMannsMPMuirAJTerraultNAJacobsonIM 2010 Telaprevir for previously treated chronic HCV infection. N Engl J Med 362 1292 1303

33. AkutaNSuzukiFHirakawaMKawamuraYYatsujiH 2010 Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52 421 429

34. AskariehGAlsioAPugnalePNegroFFerrariC 2010 Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 51 1523 1530